PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study.
Adaptive radiotherapy
Lung cancer
Non small cell lung cancer
PET/CT
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
09 Feb 2022
09 Feb 2022
Historique:
received:
22
10
2021
accepted:
25
01
2022
entrez:
10
2
2022
pubmed:
11
2
2022
medline:
18
3
2022
Statut:
epublish
Résumé
Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC. A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side. Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89-1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56-1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41-0.94). A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning.
Sections du résumé
BACKGROUND
BACKGROUND
Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC.
METHOD AND PATIENTS
METHODS
A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side.
RESULTS
RESULTS
Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89-1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56-1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41-0.94).
CONCLUSION
CONCLUSIONS
A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning.
Identifiants
pubmed: 35139856
doi: 10.1186/s13014-022-01997-5
pii: 10.1186/s13014-022-01997-5
pmc: PMC8827193
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : WI 830/12-1
Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Pak Med Assoc. 2020 Jan;70(1):29-34
pubmed: 31954019
Oncol Lett. 2014 Apr;7(4):1015-1020
pubmed: 24944661
Strahlenther Onkol. 2021 May;197(5):385-395
pubmed: 33410959
Radiother Oncol. 2017 Apr;123(1):71-77
pubmed: 28284494
Radiother Oncol. 2014 Dec;113(3):303-9
pubmed: 25458128
Front Oncol. 2020 Dec 09;10:564857
pubmed: 33363005
Dtsch Arztebl Int. 2021 Mar 26;118(12):205-211
pubmed: 34024324
J Clin Oncol. 2020 Mar 1;38(7):706-714
pubmed: 31841363
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):435-48
pubmed: 16198064
Acta Oncol. 2018 Jun;57(6):813-819
pubmed: 29205088
J Natl Compr Canc Netw. 2018 Jul;16(7):807-821
pubmed: 30006423
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):622-631
pubmed: 28581404
Lung Cancer. 2012 Feb;75(2):141-5
pubmed: 21920625
Lancet Oncol. 2020 Apr;21(4):581-592
pubmed: 32171429
Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):956-63
pubmed: 23845844
Case Rep Oncol. 2019 Aug 6;12(2):621-624
pubmed: 31543778
Eur Respir Rev. 2019 Jul 8;28(152):
pubmed: 31285288
Radiother Oncol. 2015 Jul;116(1):27-34
pubmed: 25869338
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
J Thorac Oncol. 2019 Feb;14(2):298-303
pubmed: 30292852
Radiat Oncol. 2018 Oct 23;13(1):208
pubmed: 30352608
Acta Oncol. 2015;54(9):1438-44
pubmed: 26405809
Radiat Oncol. 2018 Aug 13;13(1):147
pubmed: 30103774
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):730-737
pubmed: 29248169